BIOFRONTERA INC (BFRI) Fundamental Analysis & Valuation
NASDAQ:BFRI • US09077D2099
Current stock price
0.8696 USD
0 (-0.05%)
Last:
This BFRI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BFRI Profitability Analysis
1.1 Basic Checks
- BFRI had negative earnings in the past year.
- BFRI had a negative operating cash flow in the past year.
- In the past 5 years BFRI always reported negative net income.
- In the past 5 years BFRI always reported negative operating cash flow.
1.2 Ratios
- BFRI's Return On Assets of -113.99% is on the low side compared to the rest of the industry. BFRI is outperformed by 77.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -113.99% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-51.23%
ROA(5y)-54.01%
ROE(3y)-274.43%
ROE(5y)-268.87%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With a decent Gross Margin value of 64.41%, BFRI is doing good in the industry, outperforming 73.06% of the companies in the same industry.
- In the last couple of years the Gross Margin of BFRI has remained more or less at the same level.
- The Profit Margin and Operating Margin are not available for BFRI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.41% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y-0.95%
2. BFRI Health Analysis
2.1 Basic Checks
- BFRI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, BFRI has more shares outstanding
- Compared to 5 years ago, BFRI has more shares outstanding
- The debt/assets ratio for BFRI is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -13.01, we must say that BFRI is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -13.01, BFRI is not doing good in the industry: 77.72% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -13.01 |
ROIC/WACCN/A
WACC17.63%
2.3 Liquidity
- A Current Ratio of 1.15 indicates that BFRI should not have too much problems paying its short term obligations.
- Looking at the Current ratio, with a value of 1.15, BFRI is doing worse than 79.27% of the companies in the same industry.
- A Quick Ratio of 0.80 indicates that BFRI may have some problems paying its short term obligations.
- BFRI has a worse Quick ratio (0.80) than 80.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.15 | ||
| Quick Ratio | 0.8 |
3. BFRI Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 66.55% over the past year.
- BFRI shows a small growth in Revenue. In the last year, the Revenue has grown by 5.11%.
- BFRI shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.35% yearly.
EPS 1Y (TTM)66.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.73%
Revenue 1Y (TTM)5.11%
Revenue growth 3Y15.69%
Revenue growth 5Y7.35%
Sales Q2Q%-22.46%
3.2 Future
- The Earnings Per Share is expected to grow by 26.71% on average over the next years. This is a very strong growth
- BFRI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.86% yearly.
EPS Next Y65.92%
EPS Next 2Y40.68%
EPS Next 3Y26.71%
EPS Next 5YN/A
Revenue Next Year3.66%
Revenue Next 2Y7.25%
Revenue Next 3Y10.94%
Revenue Next 5Y14.86%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. BFRI Valuation Analysis
4.1 Price/Earnings Ratio
- BFRI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Also next year BFRI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- BFRI's earnings are expected to grow with 26.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.68%
EPS Next 3Y26.71%
5. BFRI Dividend Analysis
5.1 Amount
- BFRI does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
BFRI Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:BFRI (3/13/2026, 8:11:27 PM)
0.8696
0 (-0.05%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12 2025-11-12/amc
Earnings (Next)03-19 2026-03-19/amc
Inst Owners17.2%
Inst Owner Change-0.63%
Ins Owners4.7%
Ins Owner Change21.28%
Market Cap10.13M
Revenue(TTM)37.16M
Net Income(TTM)-17.57M
Analysts82.5
Price Target6.12 (603.77%)
Short Float %4.61%
Short Ratio0.79
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.93%
Min EPS beat(2)-33.05%
Max EPS beat(2)-4.8%
EPS beat(4)0
Avg EPS beat(4)-258.14%
Min EPS beat(4)-880.39%
Max EPS beat(4)-4.8%
EPS beat(8)1
Avg EPS beat(8)-142.95%
EPS beat(12)1
Avg EPS beat(12)-106.93%
EPS beat(16)4
Avg EPS beat(16)-70.42%
Revenue beat(2)1
Avg Revenue beat(2)2.27%
Min Revenue beat(2)-2.13%
Max Revenue beat(2)6.66%
Revenue beat(4)1
Avg Revenue beat(4)-7.73%
Min Revenue beat(4)-20.19%
Max Revenue beat(4)6.66%
Revenue beat(8)1
Avg Revenue beat(8)-10.92%
Revenue beat(12)2
Avg Revenue beat(12)-8.47%
Revenue beat(16)2
Avg Revenue beat(16)-7.07%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)30%
EPS NY rev (1m)3.47%
EPS NY rev (3m)7.95%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.27 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.91
EYN/A
EPS(NY)-0.09
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS3.19
BVpS-0.22
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -113.99% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.41% | ||
| FCFM | N/A |
ROA(3y)-51.23%
ROA(5y)-54.01%
ROE(3y)-274.43%
ROE(5y)-268.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.08%
GM growth 5Y-0.95%
F-Score3
Asset Turnover2.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | -0.93% | ||
| Cap/Sales | 0.01% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.15 | ||
| Quick Ratio | 0.8 | ||
| Altman-Z | -13.01 |
F-Score3
WACC17.63%
ROIC/WACCN/A
Cap/Depr(3y)7.65%
Cap/Depr(5y)4.96%
Cap/Sales(3y)0.1%
Cap/Sales(5y)0.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.73%
EPS Next Y65.92%
EPS Next 2Y40.68%
EPS Next 3Y26.71%
EPS Next 5YN/A
Revenue 1Y (TTM)5.11%
Revenue growth 3Y15.69%
Revenue growth 5Y7.35%
Sales Q2Q%-22.46%
Revenue Next Year3.66%
Revenue Next 2Y7.25%
Revenue Next 3Y10.94%
Revenue Next 5Y14.86%
EBIT growth 1Y8.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year56.04%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y50.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y50.61%
OCF growth 3YN/A
OCF growth 5YN/A
BIOFRONTERA INC / BFRI Fundamental Analysis FAQ
What is the fundamental rating for BFRI stock?
ChartMill assigns a fundamental rating of 2 / 10 to BFRI.
What is the valuation status for BFRI stock?
ChartMill assigns a valuation rating of 1 / 10 to BIOFRONTERA INC (BFRI). This can be considered as Overvalued.
What is the profitability of BFRI stock?
BIOFRONTERA INC (BFRI) has a profitability rating of 1 / 10.
What is the expected EPS growth for BIOFRONTERA INC (BFRI) stock?
The Earnings per Share (EPS) of BIOFRONTERA INC (BFRI) is expected to grow by 65.92% in the next year.